Results 51 to 60 of about 1,389,538 (204)

Potential value of slow‐wave sleep in management of chronic insomnia disorder

open access: yesSleep Research, EarlyView.
Abstract Chronic insomnia disorder (CID), acknowledged as the most common sleep disorder, has traditionally been diagnosed and managed with a focus on reducing sleep onset latency and extending total sleep duration. However, the critical importance of slow‐wave sleep (SWS), a key indicator of objective sleep quality, has been largely overlooked in ...
Liping Zhang   +4 more
wiley   +1 more source

Orexin Receptor-1 (OX1R)

open access: yes, 2016
Orexin or hypocretin; a peptide that resembles the molecular structure of the gastric peptide secretin, was discovered in 1996 by two independent groups of researchers.
Selena E. Bartlett   +5 more
core   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

The orexinergic system mediates the excitatory effects of caffeine on the arousal and sympathetic activity

open access: yesHeliyon, 2023
Objective: Caffeine is a non-selective adenosine receptor antagonist with pro-arousal and pro-sympathetic nervous system excitatory effects, and these pharmacological effects fit well with the physiological functions of orexin.
Yan Li   +5 more
doaj   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

In Silico to In Cerebro-Development of the Orexin Receptor Antagonist "Photorexant" for Photomodulation In Vitro and in Mouse Brains. [PDF]

open access: yesAngew Chem Int Ed Engl
Following a structure‐based design approach, photoswitchable derivatives of the FDA‐approved drug suvorexant were designed, docked, synthesized, and characterized pharmacologically at the orexin 1 and 2 receptors (OX1R and OX2R). Optimized “photorexant” showed up to an 11‐fold difference in IC50 between photoisomers, enabled dynamic and reversible ...
Angermann M   +10 more
europepmc   +2 more sources

Novel targets in headache: A narrative review

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra   +5 more
wiley   +1 more source

Use of Dual Orexin Receptor Antagonists for Insomnia and the Risk of Falls and Fractures: A Systematic Review and Meta‐Analysis

open access: yesJournal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Falls are the leading cause of injury in older adults. Sedative‐hypnotic use is a known risk factor, but their use for insomnia continues to be common. Dual orexin receptor antagonists (DORAs) are a new, potentially safer class of medications for insomnia.
Arianna Paolone   +5 more
wiley   +1 more source

Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z‐Drugs: A Target Trial Emulation

open access: yesJournal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z‐drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study
Yuichiro Matsuo   +5 more
wiley   +1 more source

Hypocretin (orexin) regulation of sleep-to-wake transitions

open access: yesFrontiers in Pharmacology, 2014
The hypocretin (Hcrt), also known as orexin, peptides are essential for arousal stability. Here I discuss background information about the interaction of Hcrt with other neuromodulators, including norepinephrine and acetylcholine probed with optogenetics.
Luis eDe Lecea, Ramon eHuerta
doaj   +1 more source

Home - About - Disclaimer - Privacy